![]() |
Europe could face drug shortages if the US is not granted exemption from new API import requirements, according to a US chemical industry trade association. Related news |
Sanofi has ended production at a historic London facility and says it plans to turn the site into a dedicated science park.
Phyton Biotech has received European approval for a version the cancer drug API docetaxel whose production does not rely on the scarce yew tree extract used in traditional manufacturing methods.
A GlaxoSmithKline subsidiary has issued a recall of two batches of Ventolin syrup in the UK after glass fragments were found in some bottles.
The UK MHRA plans to let drugmakers import APIs that lack ‘written confirmation’ of quality if there is an overriding need to ensure continued supply.
The DEA has approved AMRI’s Burlington facility to work with Schedule 2 controlled substances, placing it in a competitive position to win contract manufacturing bids, the company says.
Pfizer has chosen three of Synexus' clinical research centres in South Africa to be a part of its 100-site INSPIRE programme based on the sites’ experience and audit history.
Ambrx and Zhejiang Medicine have selected Wuxi to accelerate the development of a potential ADC (antibody drug conjugate) targeting Her2-positive breast cancer.
CRO Parexel’s massive backlog could position the company for continued revenue growth moving forward, top executives said at recent conferences.
BioPharm America™ 2013—6th Annual International Partnering Conference
Boston, MA, USA / Conference